Business Context and Reporting Period
This Form 8-K Current Report was filed by BioXcel Therapeutics, Inc. (BTAI) on April 17, 2026, covering events occurring on April 15, 2026. The Company, incorporated in Delaware and listed on The Nasdaq Capital Market, reported the execution of amendments to its existing credit facilities.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The report focuses exclusively on capital structure adjustments related to debt financing.
- Debt Instrument: Ninth Amendment to the Credit Agreement and Guaranty (originally dated April 19, 2022).
- Equity Issuance: Warrants granted to lenders to purchase up to 1,353,729 shares of common stock.
- Exercise Price: $0.01 per share.
- Expiration: Seventh anniversary of issuance (April 15, 2033).
Material Changes
On March 27, 2026, the Company entered into the Ninth Amendment to its Credit Agreement. As a result of this amendment, on April 15, 2026, the Company granted "Amendment Warrants" to the lenders. Additionally, the Company entered into a Fourth Amended and Restated Registration Rights Agreement with the lenders to register the shares issuable under these warrants. These securities were issued in reliance on Section 4(a)(2) of the Securities Act of 1933 as an exemption from registration.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard legal disclosures regarding the unregistered sale of equity securities. The transaction is contingent upon the terms of the Ninth Amendment and the Registration Rights Agreement, copies of which are filed as Exhibits 4.1 and 4.2.
Investor Verification Checklist
- Verify the full terms of the Ninth Amendment to the Credit Agreement (Exhibit 4.1) to understand any changes to interest rates, covenants, or maturity dates.
- Review the Fourth Amended and Restated Registration Rights Agreement (Exhibit 4.2) to assess potential dilution and the timeline for the registration of the 1,353,729 warrant shares.
- Confirm the identity of the lenders (including Oaktree entities and Q Boost Holding LLC) and their current ownership stakes.
- Check subsequent filings for any exercise of the warrants or further amendments to the credit facility.